drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody; anti-GD2)
drug_description
Chimeric IgG1 monoclonal antibody targeting GD2 on neuroblastoma cells; mediates ADCC and complement-dependent cytotoxicity.
nci_thesaurus_concept_id
C1570
nci_thesaurus_preferred_term
Dinutuximab
nci_thesaurus_definition
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
drug_mesh_term
Dinutuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Other treatment
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds GD2 on tumor cells and induces immune-mediated killing via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to lysis of GD2-expressing cells.
drug_name
Dinutuximab
nct_id_drug_ref
NCT06172296